GOG 163:STUDY OF DOXORUBICIN+CISPLATIN VS DOXORUBICIN+24 HOUR PACLITA

晚期子宫内膜癌没有标准的治疗方法。 一旦肿瘤扩散到子宫以外，手术和盆腔放射治疗可能不足以控制疾病，额外的治疗可能会有所帮助。 在之前的GOG（妇科肿瘤组）研究中，化疗药物多柔比星和顺铂已被给予晚期子宫内膜癌患者，超过40%的患者对这种药物组合有反应。 另一种化疗药物紫杉醇已被证明可以缩小某些子宫内膜癌患者的肿瘤大小。 本研究的目的是确定在原发性III期和IV期或复发性子宫内膜癌患者中，紫杉醇和多柔比星治疗是否比多柔比星和顺铂治疗更有效。

There is no standard treatment for advanced endometrial cancer. Once the tumor has spread beyond the uterus, treatment with surgery ad pelvic radiation may not be sufficient to control the disease and additional therapy may be helpful. In a previous GOG (Gynecologic Oncology Group) study the chemotherapy agents, doxorubicin and cisplatin, have been given to patients with advanced endometrial cancer and over 40% of patients had a response to this combination of drugs. Another chemotherapy agent, paclitaxel, has been shown to reduce the tumor size in some patients with endometrial cancer. The purpose of this study is to determine whether treatment with paclitaxel and doxorubicin is more effective than treatment with doxorubicin and cisplatin in patients with primary Stage III and IV or recurrent endometrial cancer.